Table 3.
Anti-TNF therapy in ankylosing spondylitis – open questions
Long-term efficacy? |
Arrest of progression of ankylosis? |
Differing responses in different targets? |
Dosage? |
Intervals? |
Continous or intermittent therapy? |
Individualization of treatment? |
Long-term safety? |
Repeated screening for autoantibodies? |
Adding of DMARDs to suppress antibody formation? |
Duration of tuberculosis prophylaxis? |